Authors
Latest:
How and Why the New ‘Over-Time’ Is Transforming the Work of Medical AffairsWhat’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.
Latest:
The Tech Perspective: Coordinating a Plan of EngagementDesigning an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.
Latest:
3 Steps to Supercharge Your Rare Disease Advocacy PartnershipsHow these actions can help brand teams form effective and sustainable relationships with patient communities
Latest:
Evolving a Market Access Strategy to Improve Patient AccessDavid Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Market Access Speed Is the Next Critical Differentiator for Pharma ManufacturersNew technology forces industry to increase urgency.
Latest:
Food for Thought: Make Room for Multiple OpinionsThe rise of DOLs doesn’t mean pharma should upend KOL approach.
Latest:
Drug Launch: Winning the Evidence BattleBeyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
Latest:
A Better Way to Combat Patent TrollsCross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.
Latest:
Partnering to Respond to a Possible Nuclear ThreatRecent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Latest:
Applying the Scientific Method as the Cornerstone of Brand StrategyHow commercial teams can benefit from a more scientifically rigorous approach to insights generation
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
Maximizing China Access for Innovative TherapiesTo maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.
Latest:
Positioning Medical Information as a Trust Driver for Your BrandFour steps to maximize the impact of medical information services as an engagement gateway.
Latest:
Despite Slowing Economy, Demand for Pharma Talent RisesPharma companies need to rethink their strategies to ensure that they hire the best available talent in today's market.
Latest:
Almirall’s Garden of InnovationClay Hausmann describes how Almirall is weeding out uncertainty to sow the seeds of data-driven digital transformation.
Latest:
FDA Grants Accelerated Approval to Day One’s Ojemda for Relapsed or Refractory Pediatric Low-Grade GliomaOjemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.
Latest:
How Pharma Reps and Managers Can Work to Overcome the In-Person HCP BarrierWhile HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.
Latest:
Market Access And Treatment OutcomesShifting from the volume of data to the value of insights
Latest:
Lessons Learned Working with Millions of Patients on Specialty MedicationsAdditional assistance necessary for patients prescribed specialty therapies.
Latest:
Addressing Health Disparities Through Robust Patient Support ProgramsIdentifying unique traits in patients is key to creating the most effective support programs.
Latest:
How Cloud-Based Business Management Can Streamline Processes, Manage Reporting Better, and Create Stronger Financial ControlsThursday June 8, 2022 at 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Learn how life sciences companies can navigate growth by leveraging NetSuite for streamlined processes, better management reporting, and stronger financial controls to ensure real-time management decision-making and regulatory compliance.
Latest:
Prospective Measures to Combat Rising Drug Prices in GermanyThis article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
Latest:
Dynamic Compliance: The Best Defense for PharmaA proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
Latest:
The Biopharma SME Revolution: Opportunities & Challenges Post-COVIDAhmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.
Latest:
Taking Steps Toward a Sustainable FutureStrategies to become a Certified B Corporation, and the benefits to the industry, its stakeholders, and the world.
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
